Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events

BACKGROUND: In recent years, the BRAF-inhibitor vemurafenib has been successfully established in the therapy of advanced melanoma. Despite its superior efficacy, the use of vemurafenib is limited by frequent inflammatory cutaneous adverse events that affect patients’ quality of life and may lead to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Allergy
Autors principals: Hawerkamp, Heike C., Kislat, Andreas, Gerber, Peter A., Pollet, Marius, Rolfes, Katharina M., Soshilov, Anatoly A., Denison, Michael S., Momin, Afaque A., Arold, Stefan T., Datsi, Angeliki, Braun, Stephan A., Oláh, Péter, Lacouture, Mario E., Krutmann, Jean, Haarmann-Stemmann, Thomas, Homey, Bernhard, Meller, Stephan
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6911016/
https://ncbi.nlm.nih.gov/pubmed/31269229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.13972
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars